Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 8 of 8 publications.

Campbell K, Niare S, Herman Kuiper J. A mathematical model of cartilage regeneration after chondrocyte and stem cell implantation – II: the effects of co-implantation. J Tissue Eng. 2019 Mar 15;10:1-14. doi: 10.1177/2041731419827792

Campbell K, Naire S, Herman Kuiper J. A mathematical model of cartilage regeneration after chondrocyte and stem cell implantation – I: the effects of growth factors. J Tissue Eng. 2019 Mar;10:1-16. doi: 10.1177/2041731419827791

Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.

Herman BK, Deal LS, Kando JC, DiBenedetti DB, Nelson L, Fehnel SE, Brown TM. The use and value of the 7-item binge eating disorder screener in clinical practice. Prim Care Companion CNS Disord. 2017 Jun;19(3):16m02075.

Herman BK, Deal LS, DiBenedetti DB, Nelson L, Fehnel SE, Brown TM. Development of the 7-Item Binge Eating Disorder Screener (BEDS-7). Prim Care Companion CNS Disord. 2016 Jun;18(2). doi: 10.4088/PCC.15m01896

Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.

Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.

Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.